Blog
RSS FeedPosted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...
Posted by Michael Wonder on 17 Jul 2020
Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer
17 July 2020 - Dossiers submitted for early benefit assessments in Germany also provide information on the precise determination of the ...
Posted by Michael Wonder on 11 Jul 2020
How can cancer drug prices better match their benefits? Germany offers a cost-saving model
10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...
Posted by Michael Wonder on 07 Jul 2020
Lessons from the impact of price regulation on the pricing of anti-cancer drugs in Germany
7 July 2020 - Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly ...
Posted by Michael Wonder on 25 Jun 2020
The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany
15 June 2020 - Payers are increasingly calling for the value of new drugs to be measured explicitly. ...
Posted by Michael Wonder on 03 Jun 2020
Lower prices and greater patient access — lessons from Germany’s drug purchasing structure
3 June 2020 - The German system for determining drug prices features collective negotiations on the part of competing health plans. ...
Posted by Michael Wonder on 02 Jun 2020
Ribociclib succinate in breast cancer: added benefit for certain post-menopausal women
2 June 2020 - Re-valuations after the expiry of the time limit new data cuts confirm advantages and disadvantages ...
Posted by Michael Wonder on 14 May 2020
Belimumab in active systemic lupus erythematosus: additional benefit for children and adolescents
14 May 2020 - Addendum with a new summary; subsequent information enables the benefits to be assessed. ...
Posted by Michael Wonder on 27 Apr 2020
The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
22 April 2020 - The European Network for Health Technology Assessment (EUnetHTA) organises an annual Forum with stakeholders to receive feedback ...
Posted by Michael Wonder on 17 Apr 2020
Bayer donates 8 million chloroquine tablets to the German Federal Government
14 April 2020 - Additional donations of chloroquine sent to governments in numerous other countries. ...
Posted by Michael Wonder on 16 Mar 2020
Regulatory and health technology assessment advice on post‐licensing and post‐launch evidence generation is a foundation for lifecycle data collection for medicines
11 March 2020 - The understanding of the benefit risk profile, and relative effectiveness of a new medicinal product, are initially ...
Posted by Michael Wonder on 10 Mar 2020
HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?
10 March 2020 - For at least two decades, health technology assessment has been considered worldwide the most comprehensive and suitable ...
Posted by Michael Wonder on 25 Jan 2020
Registry-data – of sufficient quality – are suitable for the extended benefit assessment of drugs
24 January 2020 - Rapid report shows how routine practice data should be collected and processed. ...
Posted by Michael Wonder on 16 Jan 2020
Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children
15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...
Posted by Michael Wonder on 16 Jan 2020
Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit
15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...